{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:37:46Z","timestamp":1791873466975,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Taisho Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Vornorexant is a novel dual orexin receptor antagonist for insomnia treatment with the shortest half-life in its class.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to compare the next-morning residual effects of vornorexant and zopiclone following bedtime administration in healthy older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized, double-blind, placebo- and active-controlled, four-way crossover study, 16 healthy participants aged \u226565 years received single bedtime doses of vornorexant (5 and 10 mg), placebo, or zopiclone (positive control) administered during hospitalization. Pharmacodynamic endpoints were assessed 8 h after administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary endpoint, area of body sway with eyes open (calculated using the root mean square of the center of pressure), was significantly smaller in the vornorexant 5 mg and 10 mg groups compared to zopiclone (p=0.001 and 0.003, respectively), but not significantly different from placebo (p=0.289 and 0.547, respectively). Similarly, significant impairments in word recall and psychomotor vigilance task performance were observed in the zopiclone group compared to the vornorexant groups, while no such effects were seen between the vornorexant and placebo groups. No significant difference was observed in the digit symbol substitution test between groups. Somnolence was observed in one, three, and two cases treated with vornorexant 5 mg, vornorexant 10 mg, and zopiclone, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicated that vornorexant 5 mg and 10 mg did not exhibit next-morning residual effects at 8 h from bedtime administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrial.gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/<\/jats:ext-link>\n                      ): NCT05819710, registered on April 6, 2023.\n                    <\/jats:p>\n                    <jats:p>\n                      jRCT (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/jrct.mhlw.go.jp\/\" ext-link-type=\"uri\">https:\/\/jrct.mhlw.go.jp\/<\/jats:ext-link>\n                      ): jRCT2071230009, registered on April 17, 2023\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-026-07095-8","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T02:37:55Z","timestamp":1779503875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of next-morning residual effects by bedtime administration of vornorexant and zopiclone in healthy older participants: postural stability, neuropsychological functions, and subjective sleepiness in a randomized clinical study"],"prefix":"10.1007","author":[{"given":"Yusuke","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiji","family":"Kambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Imadera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Uchimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"key":"7095_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00228-003-0591-5","volume":"59","author":"H Allain","year":"2003","unstructured":"Allain H, Bentu\u00e9-Ferrer D, Tarral A et al (2003) Effects on postural oscillation and memory functions of a single dose of zolpidem 5\u00a0mg, zopiclone 3.75\u00a0mg and lormetazepam 1\u00a0mg in elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo. Eur J Clin Pharmacol 59:179\u2013188. https:\/\/doi.org\/10.1007\/s00228-003-0591-5","journal-title":"Eur J Clin Pharmacol"},{"key":"7095_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/sleep\/34.5.581","volume":"34","author":"M Basner","year":"2011","unstructured":"Basner M, Dinges DF (2011) Maximizing sensitivity of the psychomotor vigilance test (PVT) to sleep loss. Sleep 34:581\u2013591. https:\/\/doi.org\/10.1093\/sleep\/34.5.581","journal-title":"Sleep"},{"key":"7095_CR3","unstructured":"BELSOMRA\u00ae (suvorexant) tablets (2014) US prescribing information. United States Food and Drug Administration full prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/204569s010lbl.pdf. Accessed 27 November 2025"},{"key":"7095_CR4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/JCP.0000000000001439","volume":"41","author":"H Bland","year":"2021","unstructured":"Bland H, Li X, Mangin E et al (2021) Effects of Bedtime Dosing With Suvorexant and Zolpidem on Balance and Psychomotor Performance in Healthy Elderly Participants During the Night and in the Morning. J Clin Psychopharmacol 41:414\u2013420. https:\/\/doi.org\/10.1097\/JCP.0000000000001439","journal-title":"J Clin Psychopharmacol"},{"key":"7095_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11065-010-9154-6","volume":"21","author":"K Crowley","year":"2011","unstructured":"Crowley K (2011) Sleep and sleep disorders in older adults. Neuropsychol Rev 21:41\u201353. https:\/\/doi.org\/10.1007\/s11065-010-9154-6","journal-title":"Neuropsychol Rev"},{"key":"7095_CR6","first-page":"39","volume-title":"Sleep Deprivation: Clinical Issues, Pharmacology, and Sleep Loss Effects","author":"J Darrian","year":"2004","unstructured":"Darrian J, Rogers NL, Dinges DF (2004) Psychomotor Vigilance Task Performance: Neurocognitive Assay Sensitive to Sleep Loss. In: Kushida CA (ed) Sleep Deprivation: Clinical Issues, Pharmacology, and Sleep Loss Effects, 1st edn. CRC, Boca Raton, pp 39\u201370","edition":"1"},{"key":"7095_CR7","unstructured":"DAYVIGO\u2122 (lemborexant) tablets (2019) US prescribing information. United States Food and Drug Administration full prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212028s011lbl.pdf. Accessed 27 November 2025"},{"key":"7095_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s11910-023-01305-y","volume":"23","author":"N Divandari","year":"2023","unstructured":"Divandari N, Bird ML, Vakili M et al (2023) The Association Between Cognitive Domains and Postural Balance among Healthy Older Adults: A Systematic Review of Literature and Meta-Analysis. Curr Neurol Neurosci Rep 23:681\u2013693. https:\/\/doi.org\/10.1007\/s11910-023-01305-y","journal-title":"Curr Neurol Neurosci Rep"},{"key":"7095_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ypmed.2019.02.001","volume":"123","author":"Y Dong","year":"2019","unstructured":"Dong Y, Yang FM (2019) Insomnia symptoms predict both future hypertension and depression. Prev Med 123:41\u201347. https:\/\/doi.org\/10.1016\/j.ypmed.2019.02.001","journal-title":"Prev Med"},{"key":"7095_CR10","doi-asserted-by":"publisher","first-page":"115489","DOI":"10.1016\/j.bmc.2020.115489","volume":"28","author":"A Futamura","year":"2020","unstructured":"Futamura A, Suzuki R, Tamura Y et al (2020) Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia. Bioorg Med Chem 28:115489. https:\/\/doi.org\/10.1016\/j.bmc.2020.115489","journal-title":"Bioorg Med Chem"},{"key":"7095_CR11","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1136\/bmj.38623.768588.47","volume":"331","author":"J Glass","year":"2005","unstructured":"Glass J, Lanct\u00f4t KL, Herrmann N et al (2005) Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 331:1169. https:\/\/doi.org\/10.1136\/bmj.38623.768588.47","journal-title":"BMJ"},{"key":"7095_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1471-2202-14-90","volume":"14","author":"AL Gotter","year":"2013","unstructured":"Gotter AL, Winrow CJ, Brunner J et al (2013) The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neurosci 14:90. https:\/\/doi.org\/10.1186\/1471-2202-14-90","journal-title":"BMC Neurosci"},{"key":"7095_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jos.2017.06.003","volume":"22","author":"H Hagino","year":"2017","unstructured":"Hagino H, Endo N, Harada A et al (2017) Survey of hip fractures in Japan: Recent trends in prevalence and treatment. J Orthop Sci 22:909\u2013914. https:\/\/doi.org\/10.1016\/j.jos.2017.06.003","journal-title":"J Orthop Sci"},{"key":"7095_CR14","doi-asserted-by":"publisher","first-page":"e033462","DOI":"10.1136\/bmjopen-2019-033462","volume":"9","author":"H Hagiya","year":"2019","unstructured":"Hagiya H, Koyama T, Zamami Y et al (2019) Fall-related mortality trends in older Japanese adults aged\u2009\u2265\u200965 years: A nationwide observational study. BMJ Open 9:e033462. https:\/\/doi.org\/10.1136\/bmjopen-2019-033462","journal-title":"BMJ Open"},{"key":"7095_CR15","doi-asserted-by":"publisher","first-page":"103624","DOI":"10.1016\/j.jpet.2025.103624","volume":"392","author":"H Hikichi","year":"2025","unstructured":"Hikichi H, Tokumaru Y, Taruta A et al (2025) Preclinical pharmacological profiles of vornorexant, a novel potent dual orexin receptor antagonist. J Pharmacol Exp Ther 392:103624. https:\/\/doi.org\/10.1016\/j.jpet.2025.103624","journal-title":"J Pharmacol Exp Ther"},{"key":"7095_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/sleep\/29.3.299","volume":"29","author":"DR Hillman","year":"2006","unstructured":"Hillman DR, Murphy AS, Pezzullo L (2006) The economic cost of sleep disorders. Sleep 29:299\u2013305. https:\/\/doi.org\/10.1093\/sleep\/29.3.299","journal-title":"Sleep"},{"key":"7095_CR17","first-page":"61","volume":"20","author":"S Isawa","year":"2000","unstructured":"Isawa S, Suzuki M, Uchiumi M et al (2000) The effect of zolpidem and zopiclone on memory. Nihon Shinkei Seishin Yakurigaku Zasshi 20:61\u201369","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi"},{"key":"7095_CR18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fnbeh.2018.00327","volume":"12","author":"S Iwakawa","year":"2019","unstructured":"Iwakawa S, Kanmura Y, Kuwaki T (2019) Orexin Receptor Blockade-Induced Sleep Preserves the Ability to Wake in the Presence of Threat in Mice. Front Behav Neurosci 12:327. https:\/\/doi.org\/10.3389\/fnbeh.2018.00327","journal-title":"Front Behav Neurosci"},{"key":"7095_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/JCP.0000000000000941","volume":"38","author":"J Jaeger","year":"2018","unstructured":"Jaeger J (2018) Digit Symbol Substitution Test: The case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol 38:513\u2013519. https:\/\/doi.org\/10.1097\/JCP.0000000000000941","journal-title":"J Clin Psychopharmacol"},{"key":"7095_CR20","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.clinph.2006.03.011","volume":"117","author":"K Kaida","year":"2006","unstructured":"Kaida K, Takahashi M, Akerstedt T et al (2006) Validation of the Karolinska sleepiness scale against performance and EEG variables. Clin Neurophysiol 117:1574\u20131581. https:\/\/doi.org\/10.1016\/j.clinph.2006.03.011","journal-title":"Clin Neurophysiol"},{"key":"7095_CR21","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/bcpt.13930","volume":"133","author":"D Kambe","year":"2023","unstructured":"Kambe D, Hasegawa S, Imadera Y et al (2023) Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant\/TS-142 in healthy Japanese participants following single\/multiple dosing: Randomized, double-blind, placebo-controlled phase-1 studies. Basic Clin Pharmacol Toxicol 133:576\u2013591. https:\/\/doi.org\/10.1111\/bcpt.13930","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"7095_CR22","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1016\/S0140-6736(05)67604-0","volume":"366","author":"P Kannus","year":"2005","unstructured":"Kannus P, Siev\u00e4nen H, Palvanen M et al (2005) Prevention of falls and consequent injuries in elderly people. Lancet 366:1885\u20131893. https:\/\/doi.org\/10.1016\/S0140-6736(05)67604-0","journal-title":"Lancet"},{"key":"7095_CR23","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/02698811241293997","volume":"39","author":"M Magliocca","year":"2025","unstructured":"Magliocca M, Koopmans I, Vaillant C et al (2025) Nighttime safety of daridorexant: Evaluation of responsiveness to an external noise stimulus, postural stability, walking, and cognitive function. J Psychopharmacol 39:223\u2013232. https:\/\/doi.org\/10.1177\/02698811241293997","journal-title":"J Psychopharmacol"},{"key":"7095_CR24","doi-asserted-by":"publisher","first-page":"M72","DOI":"10.1093\/geronj\/49.2.M72","volume":"49","author":"BE Maki","year":"1994","unstructured":"Maki BE, Holliday PJ, Topper AK (1994) A prospective study of postural balance and risk of falling in an ambulatory and independent elderly population. J Gerontol 49:M72\u201384. https:\/\/doi.org\/10.1093\/geronj\/49.2.M72","journal-title":"J Gerontol"},{"key":"7095_CR25","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5664\/jcsm.8294","volume":"16","author":"P Murphy","year":"2020","unstructured":"Murphy P, Kumar D, Zammit G et al (2020) Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening. J Clin Sleep Med 16:765\u2013773. https:\/\/doi.org\/10.5664\/jcsm.8294","journal-title":"J Clin Sleep Med"},{"key":"7095_CR26","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.juro.2010.05.093","volume":"184","author":"H Nakagawa","year":"2010","unstructured":"Nakagawa H, Niu K, Hozawa A et al (2010) Impact of nocturia on bone fracture and mortality in older individuals: A Japanese longitudinal cohort study. J Urol 184:1413\u20131418. https:\/\/doi.org\/10.1016\/j.juro.2010.05.093","journal-title":"J Urol"},{"key":"7095_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/smrv.2002.0186","volume":"6","author":"MM Ohayon","year":"2002","unstructured":"Ohayon MM (2002) Epidemiology of insomnia: What we know and what we still need to learn. Sleep Med Rev 6:97\u2013111. https:\/\/doi.org\/10.1053\/smrv.2002.0186","journal-title":"Sleep Med Rev"},{"key":"7095_CR28","doi-asserted-by":"publisher","first-page":"1146550","DOI":"10.3389\/fnhum.2023.1146550","volume":"14","author":"T Paillard","year":"2023","unstructured":"Paillard T (2023) Detrimental effects of sleep deprivation on the regulatory mechanisms of postural balance: a comprehensive review. Front Hum Neurosci 14:1146550. https:\/\/doi.org\/10.3389\/fnhum.2023.1146550","journal-title":"Front Hum Neurosci"},{"key":"7095_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/JU.0000000000000459","volume":"203","author":"JS Pesonen","year":"2020","unstructured":"Pesonen JS, Vernooij RWM, Cartwright R et al (2020) The impact of nocturia on falls and fractures: A systematic review and meta-analysis. J Urol 203:674\u2013683. https:\/\/doi.org\/10.1097\/JU.0000000000000459","journal-title":"J Urol"},{"key":"7095_CR30","unstructured":"QUVIVIQ\u2122 (daridorexant) tablets (2022) US prescribing information. United States Food and Drug Administration full prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/214985s010s012lbl.pdf. Accessed 27 November 2025"},{"key":"7095_CR31","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.biopsych.2010.10.023","volume":"69","author":"T Roth","year":"2011","unstructured":"Roth T, Coulouvrat C, Hajak G et al (2011) Prevalence and perceived health associated with insomnia based on DSM-IV-TR; international statistical classification of diseases and related health problems, tenth revision; and research diagnostic criteria\/international classification of sleep disorders, second edition criteria: results from the America insomnia survey. Biol Psychiatry 69:592\u2013600. https:\/\/doi.org\/10.1016\/j.biopsych.2010.10.023","journal-title":"Biol Psychiatry"},{"key":"7095_CR32","doi-asserted-by":"publisher","first-page":"17477","DOI":"10.1038\/s41598-023-44790-4","volume":"13","author":"R Stemplewski","year":"2023","unstructured":"Stemplewski R, Ci\u0105\u017cy\u0144ska J, Cyma-Wejchenig M et al (2023) The effect of sleep deprivation on postural stability among physically active young adults. Sci Rep 13:17477. https:\/\/doi.org\/10.1038\/s41598-023-44790-4","journal-title":"Sci Rep"},{"key":"7095_CR33","doi-asserted-by":"publisher","first-page":"8809","DOI":"10.3390\/ijerph19148809","volume":"19","author":"A Tetych","year":"2022","unstructured":"Tetych A, Olchowik G, Warcho\u0142 J (2022) Investigations concerning the influence of sleep disorders on postural stability in young men. Int J Enviro Res Public Health 19:8809. https:\/\/doi.org\/10.3390\/ijerph19148809","journal-title":"Int J Enviro Res Public Health"},{"key":"7095_CR34","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1248\/bpb.b19-00684","volume":"43","author":"H Torii","year":"2020","unstructured":"Torii H, Ando M, Tomita H et al (2020) Association of hypnotic drug Use with fall incidents in hospitalized elderly patients: A case-crossover study. Biol Pharm Bull 43:925\u2013931. https:\/\/doi.org\/10.1248\/bpb.b19-00684","journal-title":"Biol Pharm Bull"},{"key":"7095_CR35","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","volume":"239","author":"M Uchiyama","year":"2022","unstructured":"Uchiyama M, Kambe D, Imadera Y et al (2022) Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study. Psychopharmacology 239:2143\u20132154. https:\/\/doi.org\/10.1007\/s00213-022-06089-6","journal-title":"Psychopharmacology"},{"key":"7095_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaf291","author":"M Uchiyama","year":"2025","unstructured":"Uchiyama M, Kambe D, Hasegawa S et al (2025) Efficacy and safety of vornorexant in Japanese patients with insomnia: A randomized, placebo-controlled phase 3 pivotal study. Sleep press. https:\/\/doi.org\/10.1093\/sleep\/zsaf291","journal-title":"Sleep press"},{"key":"7095_CR37","doi-asserted-by":"publisher","unstructured":"Vermeeren A, Riedel WJ, van Boxtel MP et al (2002) Differential residual effects of zaleplon and zopiclone on actual driving: a comparison with a low dose of alcohol. Sleep25:224\u2013231. https:\/\/doi.org\/10.1093\/sleep\/25.2.224","DOI":"10.1093\/sleep\/25.2.224"},{"key":"7095_CR38","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.5665\/sleep.5168","volume":"38","author":"A Vermeeren","year":"2015","unstructured":"Vermeeren A, Sun H, Vuurman EF et al (2015) On-the-road driving performance the morning after bedtime use of suvorexant 20 and 40\u00a0mg: A study in non-elderly healthy volunteers. Sleep 38:1803\u20131813. https:\/\/doi.org\/10.5665\/sleep.5168","journal-title":"Sleep"},{"key":"7095_CR39","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00213-016-4375-x","volume":"233","author":"A Vermeeren","year":"2016","unstructured":"Vermeeren A, Vets E, Vuurman EF et al (2016) On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30\u00a0mg in healthy elderly. Psychopharmacology 233:3341\u20133351. https:\/\/doi.org\/10.1007\/s00213-016-4375-x","journal-title":"Psychopharmacology"},{"key":"7095_CR40","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.2337\/dc09-0284","volume":"32","author":"AN Vgontzas","year":"2009","unstructured":"Vgontzas AN, Liao D, Pejovic S et al (2009) Insomnia with objective short sleep duration is associated with type 2 diabetes: A population-based study. Diabetes Care 32:1980\u20131985. https:\/\/doi.org\/10.2337\/dc09-0284","journal-title":"Diabetes Care"},{"key":"7095_CR41","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1001\/archinternmed.2009.357","volume":"169","author":"JC Woolcott","year":"2009","unstructured":"Woolcott JC, Richardson KJ, Wiens MO et al (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169:1952\u20131960. https:\/\/doi.org\/10.1001\/archinternmed.2009.357","journal-title":"Arch Intern Med"},{"key":"7095_CR42","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/sleep\/33.12.1693","volume":"33","author":"E Yokoyama","year":"2010","unstructured":"Yokoyama E, Kaneita Y, Saito Y et al (2010) Association between depression and insomnia subtypes: A longitudinal study on the elderly in Japan. Sleep 33:1693\u20131702. https:\/\/doi.org\/10.1093\/sleep\/33.12.1693","journal-title":"Sleep"},{"key":"7095_CR43","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.5664\/jcsm.11326","volume":"20","author":"X Zhang","year":"2024","unstructured":"Zhang X, Sun Y, Ye S et al (2024) Associations between insomnia and cardiovascular diseases: A meta-review and meta-analysis of observational and Mendelian randomization studies. J Clin Sleep Med 20:1975\u20131984. https:\/\/doi.org\/10.5664\/jcsm.11326","journal-title":"J Clin Sleep Med"},{"key":"7095_CR44","doi-asserted-by":"publisher","first-page":"1029554","DOI":"10.3389\/fnhum.2022.1029554","volume":"16","author":"M Zhou","year":"2022","unstructured":"Zhou M, Tang J, Li S et al (2022) Orexin dual receptor antagonists, zolpidem, zopiclone, eszopiclone, and cognitive research: A comprehensive dose-response meta-analysis. Front Hum Neurosci 16:1029554. https:\/\/doi.org\/10.3389\/fnhum.2022.1029554","journal-title":"Front Hum Neurosci"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07095-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-026-07095-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-026-07095-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T02:37:58Z","timestamp":1779503878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-026-07095-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":44,"alternative-id":["7095"],"URL":"https:\/\/doi.org\/10.1007\/s00213-026-07095-8","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Hakata Clinic Institutional Review Board (approval no. 1546P1CP-10) on May 11, 2023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of study approval by the appropriate ethics committee"}},{"value":"All participants were provided with sufficient information to make a decision to get involved in the study and written informed consent was obtained from them before enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"YM, DK, YI, and HY are employees of Taisho Pharmaceutical Co. Ltd. NU received grants from Eisai Co., Ltd.; Otsuka Pharmaceutical Co., Ltd.; Merck Sharp & Dohme; and Takeda Pharmaceutical Co., Ltd. MU provided consulting services and received personal fees from Alfresa Pharma Co.; Nxera Pharma Japan Co., Ltd.; Lixil Co.; Sanofi S.A.; and Taisho Pharmaceutical Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}